LY2140023 meets Phase II schizophrenia endpoint

Eli Lilly (LLY) said LY2140023 met the primary endpoint of a significant improvement in total positive and negative syndrome scale (PANSS) scores vs. placebo at week four in a Phase II trial to treat ...